Ascentage Pharma Group International (AAPG) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · United States · ISIN US04390B1052
Ascentage Pharma Group International financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 980.65 m CNY | 558.48 m CNY |
| Gross profit | 951.57 m CNY | 426.75 m CNY |
| Operating income | -369.73 m CNY | -1.18 bn CNY |
| EBIT | -330.80 m CNY | -1.18 bn CNY |
| Net income | -405.43 m CNY | -1.21 bn CNY |
| Diluted EPS – continuing operations | -5.37 CNY | -13.58 CNY |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Ascentage Pharma Group International
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has strategic partnership with biotechnology and pharmaceutical companies; research institutions; and Peking University to build a collaborative system for hematological oncology. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
More stocks
- InnovAge Holding Corp. (INNV)
- Central Reinsurance Corp (2851.TW)
- H&K (MLHK.PA)
- LHV Group AS (LHV1T.TL)
- Shandong Bailong Chuangyuan Bio-Tech Co. Ltd. (605016.SS)
- Guangdong Skychem Technology Co. Ltd. A (688603.SS)
- Impax Environmental Markets PLC (IEM.L)
- Ivanhoe Electric Inc. (IE)
- Tianrun Crankshaft Co Ltd (002283.SZ)
- Farmers And Merchants Bank of Long Beach (FMBL)
- Sociedad Matriz SAAM SA (SMSAAM.SN)
- Via Transportation, Inc. (VIA)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.